title: Antiangiogenic drugs for chemotherapy of bladder tumours.
abstract: BACKGROUND
  Bladder cancers have different angiogenic pathways distinguishing not only papillary from solid tumours, but even papillary superficial from papillary invasive ones, thus representing selective targets for antiangiogenic drugs.
  
  
  METHODS
  The bacterial wall component tecogalan, inhibiting basic fibroblast growth factor (bFGF), the fumagillin derivative TNP-470, inhibiting vascular endothelial growth factor (VEGF), the distamycin A derivative PNU153429, and the tetracycline minocycline were administered to nude mice injected with the human bladder cancer cell lines 639V, causing bFGF-expressing papillary superficial tumours, or T24, causing VEGF-expressing papillary invasive tumours.
  
  
  RESULTS
  Tecogalan had no effect even on 639V tumour growth, where bFGF was unaffected. TNP-470 only had an effect on T24 tumours, delaying tumour appearance and growth and lowering VEGF; these effects were augmented by adding minocycline. PNU153429 had no effect on 639V tumours, and a slight effect on T24 tumours.
  
  
  CONCLUSIONS
  TNP-470 may represent a selective drug for the treatment of VEGF-expressing invasive papillary bladder tumours.
authors.affiliation: Institute of Microbiology and Biomedical Sciences, Polytechnic University of Marche, Ancona, Italy.
authors.forename: Romina
authors.initials: R
authors.lastname: Rocchetti
authors.forename: Simona
authors.initials: S
authors.lastname: Talevi
authors.forename: Chiara
authors.initials: C
authors.lastname: Margiotta
authors.forename: Roberta
authors.initials: R
authors.lastname: Calza
authors.forename: Alfredo
authors.initials: A
authors.lastname: Corallini
authors.forename: Laura
authors.initials: L
authors.lastname: Possati
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D002291:Carcinoma, Papillary / Q000188:drug therapy* / Q000473:pathology; D045744:Cell Line, Tumor; D003510:Cyclohexanes; D004214:Distamycins / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D008911:Minocycline / Q000008:administration & dosage / Q000494:pharmacology; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D047495:PPAR gamma / Q000187:drug effects / Q000378:metabolism; D011135:Polysaccharides, Bacterial / Q000494:pharmacology / Q000627:therapeutic use*; D012717:Sesquiterpenes / Q000494:pharmacology / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000187:drug effects / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D003510:Cyclohexanes; D004214:Distamycins; C113015:PNU 153429; D047495:PPAR gamma; D011135:Polysaccharides, Bacterial; D012717:Sesquiterpenes; D042461:Vascular Endothelial Growth Factor A; D016222:Fibroblast Growth Factor 2; C079061:tecogalan; D008911:Minocycline; D000077609:O-(Chloroacetylcarbamoyl)fumagillol